MedTrace Logo

Apremilast in Combination With Clobetasol Spray for the Treatment of Plaque Psoriasis

NCT03453190 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2018-03-05

No results posted yet for this study

Summary

Researchers want to find out if giving the drug Apremilast in combination with Clobetasol spray can help people clear their moderate to severe plaque psoriasis quicker than if Apremilast is used by itself.

Conditions

Interventions

COMBINATION_PRODUCT

Apremilast and Clobetasol

Patients will receive apremilast and clobetasol with tapering dosages over 16 weeks.

Sponsors & Collaborators

  • Washington Dermatology Center

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-25
Primary Completion
2020-03-01
Completion
2020-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03453190 on ClinicalTrials.gov